Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
Trastuzumab resistance is one of the causes of poor prognosis in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC). The truncated isoform of dopamine- and cAMP-regulated phosphoprotein (t-DARPP) has been reported to be involved in trastuzumab therapy r...
Saved in:
Main Authors: | Han-Sheng Chang, Tzu-Chun Cheng, Shih-Hsin Tu, Chih-Hsiung Wu, You-Cheng Liao, Jungshan Chang, Min-Hsiung Pan, Li-Ching Chen, Yuan-Soon Ho |
---|---|
Format: | Article |
Language: | English |
Published: |
Tsinghua University Press
2024-09-01
|
Series: | Food Science and Human Wellness |
Subjects: | |
Online Access: | https://www.sciopen.com/article/10.26599/FSHW.2022.9250213 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Deep learning-based prediction of HER2 status and trastuzumab treatment efficacy of gastric adenocarcinoma based on morphological features
by: Zhida Wu, et al.
Published: (2025-01-01) -
Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01) -
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01) -
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)